Cardiff Oncology News

Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036

The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society...

PR NewswireMay 10 00:15

HC Wainwright & Co. : The Cardiff Oncology (CRDF.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.

HC Wainwright & Co. : The Cardiff Oncology (CRDF.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.

Zhitong FinanceMay 6 18:31

HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $14 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cardiff Oncology (NASDAQ:CRDF) with a Buy and maintains $14 price target.

BenzingaMay 6 18:27

Cardiff Oncology Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 300% HC Wainwright & Co. → $14 Reiterates Buy → Buy 03/06/2024 300% HC Wainwright & Co. $12 → $

BenzingaMay 6 18:25

Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations

Yahoo FinanceMay 4 20:30

Earnings Call Summary | Cardiff Oncology(CRDF.US) Q1 2023 Earnings Conference

The following is a summary of the Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript:Financial Performance:Cardiff Oncology reported a total of $67.2 million in cash and short-term investm

Futu NewsMay 4 03:40 · Conference Call

Cardiff Oncology, Inc. (NASDAQ:CRDF) Q1 2023 Earnings Call Transcript

Yahoo FinanceMay 3 23:09

AEON Biopharma, Allarity Therapeutics, ModivCare Among Healthcare Movers

Seeking AlphaMay 3 22:00

Cardiff Oncology (CRDF) Gets a Buy From Piper Sandler

TipRanksMay 3 20:18

12 Health Care Stocks Moving In Friday's Pre-Market Session

GainersHelius Medical Tech (NASDAQ:HSDT) shares increased by 48.9% to $3.96 during Friday's pre-market session. The company's market cap stands at $3.5 million. Vaxxinity (NASDAQ:VAXX) shares moved up

BenzingaMay 3 20:06

Cardiff Oncology Shares Are Trading Lower. The Company Reported Q1 Financial Results.

Cardiff Oncology Shares Are Trading Lower. The Company Reported Q1 Financial Results.

BenzingaMay 3 06:17

Cardiff Oncology (CRDF.US): The 2024 Q1 financial report achieved revenue of US$205,000, with a previous value of US$83,000, with an expected value of US$50,000; earnings per share of -0.22 dollars, previous value of -0.25 dollars, expected value of -0.25

Cardiff Oncology (CRDF.US): The 2024 Q1 financial report achieved revenue of US$205,000, with a previous value of US$83,000, with an expected value of US$50,000; earnings per share of -0.22 dollars, previous value of -0.25 dollars, expected value of -0.25 dollars.

Zhitong FinanceMay 3 05:11

Cardiff Oncology Q1 2024 GAAP EPS $(0.22) Beats $(0.25) Estimate, Sales $205.000K Beat $55.000K Estimate

Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.25) by 12 percent. This is a 12 percent increase over losses of $(0.25) p

BenzingaMay 3 05:10

Cardiff Oncology 1Q Loss/Shr 22c >CRDF

Cardiff Oncology 1Q Loss/Shr 22c >CRDF

Dow JonesMay 3 04:05

Press Release: Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update - In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong

Dow JonesMay 3 04:05

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage

GlobeNewswireApr 26 04:05

Cardiff Oncology Reveals Latest Cancer Research at AACR

TipRanksApr 9 04:23

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 That Supports Ongoing First-line RAS-mutated MCRC Clinical Study

RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and

GlobeNewswireApr 9 04:05

Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?

Yahoo FinanceMar 14 20:08

12 Health Care Stocks Moving In Wednesday's Intraday Session

GainersHeron Therapeutics (NASDAQ:HRTX) shares rose 35.4% to $3.19 during Wednesday's regular session. The market value of their outstanding shares is at $479.4 million. The company's, Q4 earnings cam

BenzingaMar 14 01:31